Payment overview · 2025
General Payments
$16.97
1 reported records · 1 companies
Healthcare provider profile · identity verified
James Paul Mcdowell, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BRIDGEVILLE, PA · NPI 1386608461
Verified facts
What the public records show
CMS Open Payments records show James Paul Mcdowell, D.O. received $16.97 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 484 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.97 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 484 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
484 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 855 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 774 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 662 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 122 |
| Lisinopril | Lisinopril | 510 | 90 |
| Eliquis | Apixaban | 484 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 460 | 63 |
| Simvastatin | Simvastatin | 436 | 79 |
| Omeprazole | Omeprazole | 357 | 62 |
| Furosemide | Furosemide | 338 | 54 |
| Donepezil Hcl | Donepezil Hcl | 307 | 18 |
| Sertraline Hcl | Sertraline Hcl | 300 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 38 |
| Losartan Potassium | Losartan Potassium | 263 | 72 |
| Bumetanide | Bumetanide | 257 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 252 | 12 |
| Gabapentin | Gabapentin | 250 | 33 |
| Metformin Hcl | Metformin Hcl | 244 | 58 |
| Potassium Chloride | Potassium Chloride | 216 | 26 |
| Mirtazapine | Mirtazapine | 198 | 15 |
| Memantine Hcl | Memantine Hcl | 197 | 12 |
| Spironolactone | Spironolactone | 197 | 18 |
| Trazodone Hcl | Trazodone Hcl | 194 | 24 |
| Alprazolam | Alprazolam | 157 | 48 |
| Valsartan | Valsartan | 146 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 21 |
| Atenolol | Atenolol | 121 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 18 |
| Finasteride | Finasteride | 110 | 19 |
| Allopurinol | Allopurinol | 108 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 96 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 90 | 13 |
| Carvedilol | Carvedilol | 87 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 82 | suppressed |
| Entresto | Sacubitril/Valsartan | 80 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 80 | 13 |
| Irbesartan | Irbesartan | 78 | 14 |
| Meloxicam | Meloxicam | 78 | 14 |
| Propranolol Hcl | Propranolol Hcl | 75 | suppressed |
| Methimazole | Methimazole | 74 | suppressed |
| Prednisone | Prednisone | 72 | 19 |
| Famotidine | Famotidine | 70 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 11 |
| Alendronate Sodium | Alendronate Sodium | 64 | 13 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 19 |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Digoxin | Digoxin | 57 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | suppressed |
| Risperidone | Risperidone | 54 | suppressed |
| Loperamide | Loperamide Hcl | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | 16 |
| Ramipril | Ramipril | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 17 |
| Haloperidol | Haloperidol | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 25 |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | 12 |
| Amoxicillin | Amoxicillin | 24 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.97 · 1 records | PFIZER INC. | ELIQUIS, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error